EUVIMED · CrossrefZeitschrift
Journal of Oncology Pharmacy Practice
ISSN 1078-1552 · SAGE Publications
Neueste Artikel
Additional perspectives on survival outcomes in capecitabine-treated colorectal cancer
Reply to the letter “Additional perspectives on survival outcomes in capecitabine-treated colorectal cancer”
Comparison of carboplatin dosing derived from Cockcroft–Gault creatinine clearance and race-free CKD-EPI estimated glomerular filtration rate
Implementation of a student pharmacist–led medication review program prior to metaiodobenzylguanidine (MIBG) imaging in pediatric oncology patients
Association of medication burden and potential drug–drug interactions with acute kidney injury among critically ill patients receiving anticancer therapy at a tertiary care centre
Collaboration between clinical pharmacists and physicians to manage drug-related problems in an adult hematopoietic stem cell transplantation unit
Impact of a pharmacist-led pharmacogenomic service on test capture rates in oncology: A retrospective pre-post cohort study, 2024-2026
Compatibility of closed system transfer devices with hazardous drug vials wrapped in vial protect pack shrink tack labels: Comparative evaluation between experienced pharmacists and pharmacy students
Ruxolitinib for graft-versus-host disease prophylaxis following tacrolimus toxicity: A case series
Racial disparities in treatment patterns in patients with non-small cell lung cancer before and after approval of immune checkpoint inhibitors: A population-based study
Antibody-drug conjugate use and spending in the United States, 2013–2022
Enzalutamide alone or combined with other pharmacologic agents for metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
Drug-induced QT prolongation in oncology: A precision-medicine
Pre-ICU medication vulnerability and healthcare-access barriers associated with unplanned intensive care admission among cancer patients: A case-control study
Administration-related reactions following first-dose subcutaneous daratumumab to inform implementation of a 30-minute observation period
When hospital pharmacies procure medicines for industry-sponsored oncology trials: The hidden costs of sponsor reimbursement
Trastuzumab reloading: Regimen-specific eligibility and safety inference
Treatment patterns and healthcare utilization for patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the Veterans Health Administration (MCLOVA) who were prescribed their first Bruton Tyrosine Kinase inhibitor (BTKi): A national retrospective cohort study
Use of an abridged desensitization protocol to rechallenge oxaliplatin dosing after a suspected hypersensitivity reaction to FOLFOX: A case report
Tebentafusp desensitization in an adult with metastatic uveal melanoma
Association between the profile of patients with chronic myeloid leukemia and adherence to tyrosine kinase inhibitors
Efficacy and safety of adjuvant capecitabine and pembrolizumab in early-stage triple-negative breast cancer after standard neo-/adjuvant chemotherapy: A meta-analysis of phase III studies
Prognostic factors associated with survival in patients with colorectal cancer treated with capecitabine: A cohort study
AI adoption among French oncology pharmacists: A national survey
Efficacy and safety of ensartinib in the treatment of non-small cell lung cancer: A systematic review of clinical trials
From needs to app: A user-centred design approach for developing mobile health interventions in oncology care
Development of a unified approach to hazardous medicinal product management using closed system drug transfer devices
Cardiovascular safety of CDK4/6 inhibitors in advance breast cancer: Assessing risks of QTc prolongation and thrombosis
FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience
Cardioprotection in oncology: Mechanisms, risks and therapeutic strategies
EUVIMED